Skip to main content

Table 3 Clinical details of patients with Trifecta valve structural valve deterioration

From: Impact of postoperative patient-prosthesis mismatch as a risk factor for early structural valve deterioration after aortic valve replacement with Trifecta bioprosthesis

No. Age (years), sex Valve size (mm) Postoperative EOAI (cm2/m2) Durability (month) mPG at last follow-up TTE (mmHg) AR at last follow-up TTE Redo Indication Redo Surgery Details
1 72, F 19 0.82 4 14 3 AR SAVR Cusp tear and pannus
2 76, F 19 0.78 19 29 4 AR SAVR Cusp tear
3 76, M 21 0.94 24 26 4 AR SAVR Cusp tear and pannus
4 79, F 19 0.64 34 18 4 AR SAVR Cusp tear
5 77, M 21 0.52 49 15 3 AR SAVR Cusp tear and attachment to Valsalva sinus
6 65, F 19 0.57 67 28 3 AsR TAVR  
7 79, F 19 1.1 86 54 2 AS TAVR  
  1. F, female; M, male; mPG, mean pressure gradient; AR, aortic regurgitation; TTE, transthoracic echo; AsR, aortic stenosis and regurgitation; AS, aortic stenosis; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement